USANA Health Sciences Inc (USNA)

Liquidity ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio 2.00 3.93 4.03 3.74 3.52 3.47 3.41 3.04 2.67 2.71 2.56 2.30 2.27 2.33 2.49 2.46 2.53 2.40 2.33 2.30
Quick ratio 1.36 3.18 3.20 2.92 2.84 2.73 2.64 2.27 2.06 1.96 1.72 1.51 1.54 1.57 1.73 1.70 1.90 1.73 1.63 1.56
Cash ratio 1.30 3.18 3.20 2.92 2.78 2.73 2.64 2.27 2.01 1.96 1.72 1.51 1.49 1.57 1.73 1.70 1.86 1.73 1.63 1.56

USANA Health Sciences Inc has shown consistent improvement in its liquidity ratios over the past few years. The company's current ratio, which measures its ability to meet short-term obligations with current assets, has generally increased, indicating its strengthened liquidity position. As of December 31, 2024, the current ratio stood at 2.00, showing a slight decline from previous quarters but still within a healthy range.

Similarly, the quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, has shown a trend of improvement. As of December 31, 2024, the quick ratio was 1.36, decreasing significantly from the previous quarter but remaining above 1, indicating the company's ability to cover its short-term liabilities with its most liquid assets.

The cash ratio, representing the proportion of a company's liquid assets to its current liabilities, has also seen positive growth. As of December 31, 2024, the cash ratio stood at 1.30, showing a decrease from the previous quarter but still indicating that USANA Health Sciences Inc has an adequate level of cash to cover its short-term liabilities.

Overall, the liquidity ratios of USANA Health Sciences Inc reflect a solid financial position with a good ability to meet its short-term obligations, although a slight dip in some ratios in the most recent quarter may warrant monitoring for any potential impacts on the company's liquidity in the future.

Additional liquidity measure

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash conversion cycle days 52.99 50.03 47.88 44.92 45.91 41.92 42.86 43.48 47.30 44.11 56.77 64.43 64.33 59.66 62.78 76.15 96.41 118.34 112.76 94.81

The cash conversion cycle of USANA Health Sciences Inc has shown a consistent improvement over the past few years, indicating efficient management of its working capital. The company's cash conversion cycle decreased from 94.81 days as of March 31, 2020, to 52.99 days as of December 31, 2024. This suggests that USANA Health Sciences has been able to reduce the time it takes to convert its investments in inventory and accounts receivable into cash.

A lower cash conversion cycle indicates that the company is able to efficiently manage its inventory levels, collect receivables promptly, and negotiate favorable payment terms with suppliers. This can improve the company's liquidity position and reduce its reliance on external financing sources.

USANA Health Sciences Inc's decreasing cash conversion cycle is a positive indicator of its operational efficiency and effective working capital management. It reflects the company's ability to generate cash flow from its operational activities and reinvest it back into the business. Overall, a declining trend in the cash conversion cycle is generally favorable for a company, as it signifies improved financial health and operational performance.